Trial Profile
Phase II study of FR901228 [romidepsin] in patients with refractory or progressive small cell or non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2013
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- 31 May 2007 New trial record.